Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China

BACKGROUND. Cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) has been shown to be a promising strategy in the treatment of various malignancies. Despite the proven efficacy and tolerability of ICIs based on 113 clinical trials globally, data regarding the pharmacokinetic (PK) and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wenfeng, Zhao, Shen, Zhang, Yaxiong, Ma, Yuxiang, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Immuno‐Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394776/
https://www.ncbi.nlm.nih.gov/pubmed/30819827
http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394776/
https://www.ncbi.nlm.nih.gov/pubmed/30819827
http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s03

Ejemplares similares